Oppenheimer Initiates Coverage On Larimar Therapeutics with Outperform Rating, Announces Price Target of $26
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Larimar Therapeutics with an Outperform rating and set a price target of $26.
October 16, 2024 | 9:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Larimar Therapeutics with an Outperform rating and a price target of $26, indicating a positive outlook.
The initiation of coverage with an Outperform rating and a specific price target by a reputable firm like Oppenheimer is likely to positively influence investor sentiment and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100